
Nutranomics, Inc.
Nutranomics, Inc. (NNRX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
nnrx · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 4 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Nutranomics, Inc.You NNRX | $1M | N/A | — | -$0.00 |
Acura Pharmaceuticals, Inc. ACUR | $0M | N/A | — | -$0.02 |
Endonovo Therapeutics, Inc. ENDV | $0M | N/A | — | -$0.00 |
Filament Health Corp. FLHLF | $0M | N/A | — | -$0.02 |
Wayland Group Corp. MRRCF | $0M | N/A | — | -$0.75 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Nutranomics, Inc. (NNRX) measures how much investors pay for each dollar of the company's trailing earnings. NNRX's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of -$0.00.
Frequently asked questions
NNRX pe ratio · 6 questionsNNRX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.00 and TTM EPS of -$0.00. Data sourced from Financial Modeling Prep via NNRX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Nutranomics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09